Lung deposition after inhalation with various nebulisers in preterm infants

Archives of Disease in Childhood: Fetal and Neonatal Edition

Volumn 93, Issue 4, 2008, Pages

  Kohler E ^a   Jilg, G ^a   Avenarius, S ^a   Jorch, G ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CROMOGLYCATE DISODIUM;

ABSENCE OF SIDE EFFECTS; AEROSOL; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG URINE LEVEL; EVALUATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INHALATION; LUNG DEPOSITION; MALE; MOLECULAR SIZE; NEBULIZER; NEWBORN; PREMATURITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TECHNIQUE; URINARY EXCRETION;

ADMINISTRATION, INHALATION; ANTI-ASTHMATIC AGENTS; CROMOLYN SODIUM; FEMALE; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; LUNG; MALE; NEBULIZERS AND VAPORIZERS;

EID: 47849097922     PISSN: 13592998     EISSN: 14682052     Source Type: Journal    
DOI: 10.1136/adc.2007.121285     Document Type: Article

References (27)

1. Collis GG, Cole CH, Le Souef PN. Dilution of nebulised aerosols by air entrainment in children. Lancet 1990;336:341-3.
2. Dolovich M. Aerosol delivery to children: what to use, how to choose. Pediatr Pulmonol Suppl 1999;18:79-82.
3. Iies R, Lister P, Edmunds AT. Crying significantly reduces absorption of aerosolised drug in infants. Arch Dis Child 1999;81:163-5.
4. Murakami G, Igarashi T, Adachi Y, et al. Measurement of bronchial hyperreactivity in infants and preschool children using a new method. Ann Allergy 1990;64:383-7.
5. Cole CH. Special problems in aerosol delivery: neonatal and pediatric considerations. Respir Care 2000;45:646-51.
6. Amirav I, Balanov I, Gorenberg M, et al. Nebuliser hood compared to mask in wheezy infants: aerosol therapy without tears! Arch Dis Child 2003;88:719-23.
7. Everard ML. Ethical aspects of using radiolabelling in aerosol research. Arch Dis Child 2003;88:659-61.
8. Iqbal S, Ritson S, Prince I, et al. Drug delivery and adherence in young children. Pediatr Pulmonol 2004;37:311-7.
9. Amirav I, Mansour Y, Mandelberg A, et al. Redesigned face mask improves "real life" aerosol delivery for Nebuchamber. Pediatr Pulmonol 2004;37:172-7.
10. Gappa M, Gartner M, Poets CF, et al. Effects of salbutamol delivery from a metered dose inhaler versus jet nebulizer on dynamic lung mechanics in very preterm infants with chronic lung disease. Pediatr Pulmonol 1997;23:442-8.
11. Fok TF, Lam K, Chan CK, et al. Aerosol delivery to non-ventilated infants by metered dose inhaler: should a valved spacer be used? Pediatr Pulmonol 1997;24:204-12.
12. Deerojanawong J, Manuyakorn W, Prapphal N, et al. Randomized controlled trial of salbutamol aerosol therapy via metered dose inhaler-spacer vs. jet nebulizer in young children with wheezing. Pediatr Pulmonol 2005;39:466-72.
13. Silkstone VL, Corlett SA, Chrystyn H. Determination of the relative bioavailability of salbutamol to the lungs and systemic circulation following nebulization. Br J Clin Pharmacol 2002;54:115-9.
14. Köhler E, Sollich V, Schuster-Wonka R, et al. Lung deposition in cystic fibrosis patients using an ultrasonic or a jet nebulizer. J Aerosol Med 2003;16:37-46.
15. Köhler E, Sollich V, Schuster-Wonka R, et al. Does wearing a noseclip during inhalation improve lung deposition? J Aerosol Med 2004;17:116-22.
16. Salmon B, Wilson NM, Silverman M. How much aerosol reaches the lungs of wheezy infants and toddlers? Arch Dis Child 1990;65:401- 3.
17. Grigg J, Arnon S, Jones T, et al. Delivery of therapeutic aerosols to intubated babies. Arch Dis Child 1992;67:25-30.
18. Ng GY, Ohlsson A. Cromolyn sodium for the prevention of chronic lung disease in preterm infants. Cochrane Database Syst Rev 2001;(2):CD003059.
19. Aswania OA, Corlett SA, Chrystyn H. Relative bioavailability of sodium cromoglycate to the lung following inhalation, using urinary excretion. Br J Clin Pharmacol 1999;47:613-8.
20. Aswania O, Chrystyn H. Relative lung bioavailability of generic sodium cromoglycate inhalers used with and without a spacer device. Pulm Pharmacol Ther 2001;14:129-33.
21. Aswania O, Chrystyn H. Relative lung and systemic bioavailability of sodium cromoglycate inhaled products using urinary drug excretion post inhalation. Biopharm Drug Dispos 2002;23:159-63.
22. Shennan AT, Dunn MS, Ohlsson A, et al. Abnormal pulmonary outcomes in premature infants: prediction from oxygen requirement in the neonatal period. Pediatrics 1988;82:527-32.
23. Abbasi S, Bhutani VK. Pulmonary mechanics and energetics of normal, non-ventilated low birthweight infants. Pediatr Pulmonol 1990;8:89-95.
24. Gagliardi L, Rusconi F. Respiratory rate and body mass in the first three years of life. The working party on respiratory rate. Arch Dis Child 1997;76:151-4.
25. Köhler E, Sollich V, Schuster-Wonka R, et al. Lung deposition following electronically breath-controlled inhalation and manually triggered conventional inhalation in cystic fibrosis patients. J Aerosol Med 2005;18:386-95.
26. Neale MG, Brown K, Hodder RW, et al. The pharmacokinetics of sodium cromoglycate in man after intravenous and inhalation administration. Br J Clin Pharmacol 1986;22:373-82.
27. Walker SR, Evans ME, Richards AJ, et al. The fate of (14 C)disodium cromoglycate in man. J Pharm Pharmacol 1972;24:525-31.